A series of near-infrared (NIR)-emitting cyclometalated rhodium(III) complexes have been designed, synthesized and characterized. The NIR luminescence has been realized by rational design of strong σ-donor cyclometalating (C^N) ligand with extended π-conjugation structure for decreasing the energy level of intraligand (IL) state. In addition, the investigation of substituents on the benzo[g]quinoxaline moiety as the carbon-donor demonstrated that the luminescence can be further shifted to the red by the introduction of electrondonating thienyl groups. The luminescence maxima of these complexes are ranging from 763 nm to 792 nm with the luminescence quantum yield (Φ lum ) of 0.41 %-0.66 % in dichloromethane solution. This work demonstrates the first example of NIR-phosphorescent rhodium(III) complexes and provides an alternative for diversifying the development of NIR materials.
The Front Cover shows two cyclometalated rhodium(III) complexes with near‐infrared (NIR) luminescence, which are the first examples of NIR‐phosphorescent rhodium(III) complexes. The NIR luminescence has been achieved by rational design of a strong σ‐donor cyclometalating (C N) ligand with extended π‐conjugation for decreasing the energy level of the intraligand (IL) state. A thorough understanding of the substituents on the benzo[g]quinoxaline moiety as the carbon‐donor demonstrated that the luminescence can be further shifted to the red by the introduction of electron‐donating thienyl groups. The luminescence maxima of these two complexes range from 763 nm to 792 nm. More information can be found in the Research Article by F. Wei, K. M.‐C. Wong and co‐workers.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.